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New Jersey Institute of Technology 
College of Science & Liberal Arts 




Course: CHEM 702: ST: Regulatory Compliance in Applied Cell & Gene Therapy 
Spring 2020, 15-Weeks  
January 23, 2020 – May 14, 2020 
Meeting Time: Thursdays, 6:00 PM – 8:50 PM 
Meeting Location: TIER 113 
Professor name: Zainab H. Alali, PhD 
E-mail: alali@njit.edu 
Phone Number: 973-596-5297 
In general, please contact me by e-mail and you will get a response within 24-48 hours. I can 
meet you by appointment only.  
 
Overview: 
The objective of the course is to provide an overview of Regulatory Affairs for Cell and Gene Therapy 
Product approval. We will examine every step of the regulatory process for Cell and Gene Therapy 
products from preclinical testing through commercialization and post-marketing. This course will offer 
students an opportunity to conduct a comprehensive and up-to-date analysis of the complete U.S. 
pharmaceutical Cell and Gene Therapy regulatory and product approval processes. We will discuss the 
FDA’s standards for preclinical testing, quality assurance, good laboratory and manufacturing practices, 
investigational new drug (IND) and NDA applications, therapeutic market applications and FDA’s review 
process. In addition, the regulatory process for approval of Gene and Cell Therapy products in the EU 
and Japan will be discussed. 
 
Weekly Time Commitment:   
2 
 
It is estimated that students will spend an average of 3 hours per week on this course. The amount of 
time that will be required will vary from week to week. This time commitment is consistent with the 
accepted standards for a three-credit, graduate-level course. 
Academic Integrity:  
All students must observe and support high standards of honesty and integrity in all aspects of 
education, practice, and research. For this reason, all students in this course are expected to abide by 
the School's Faculty/Student Honor Code and accept responsibility to help ensure that these standards 
are maintained by reporting violations of the Honor Code observed in others. All academic integrity 
violations will be considered with the gravest concern and may be punishable with sanctions as severe 
as suspension or dismissal. 
Grading Explanation: 
 
Deliverable Percentage Due Date 
Midterm 30 % 3/5/20 
Oral Presentation 30 % 4/16/20- 4/23/20 
Participation in Class 10 % All semester 
Final Exam 30 % 4/30/20 
Total 100 %  
 
 
Topics to be Covered: 
 (This is a plan and may be subject to change) 
Week Topic Description 
1- 1/23/20 Overview of Regulatory Affairs  What is Regulatory 
Affairs? 





Regulatory Agencies and 
Organizations. 
 What is the US Food and 
Drug Administration 
(FDA) roles? 
 The roles of the US Food 
and Drug Administration 
(FDA). 
2- 1/30/20 The Drug and Biologic Product 
Development Process 




 What drug and biologic 
products are? And what 
are the differences 
between them? 
 The general stages of 
therapeutic product 
development from R&D to 
marketing. 
 The various types of 
manufacturer – FDA 
interactions that can and 
should occur during the 
drug development 
process. 
3- 2/6/20 The Gene and Cell Therapy  What is Gene and Cell 
Therapy mean? 
 The difference between 
Cell and Gene therapy. 
 Examples of Gene and Cell 
Therapy. 
 Major companies and 
their products in Gene and 
Cell Therapy. 
 An overview of the 
additional manufacturing 
challenges with these 
types of products. 
4- 2/13/20 Deviations and CAPAs  What are deviations and 
CAPAs? 
 Why Deviations and 
CAPAs are important for 
getting approval of new 
therapy products with 
FDA. 
 Types of deviations and 
CAPAs. 
 Examples and case 
studies.  
5- 2/20/20 FDA registration   How to register a new 
GMP center with FDA. 
 Challenges and solutions. 
 Overview of FDA 
registration website. 
 
6- 2/27/20 Pre-Investigational New Drug (Pre-
IND) 
 Explain the purpose of 




 Identify the non-clinical 
required components of 
the IND for initial IND 
approval. 
 Describe the differences in 
nonclinical testing of drugs 
and biologics. 
 Explain the informal pre-
IND process of the Office 
of Tissues and Advanced 
Therapies. 
 Describe the pre-IND 
Meeting process. 
7- 3/5/20 Midterm Will cover materials from 
week 1- week 6. 
8- 3/12/20 Commercializing a Gene and Cell 
Therapy 
 Overview of the 
Regulatory Path to 
Commercializing a Gene 
Therapy. 
 Overview of the 
Regulatory Path to 
Commercializing a Cell 
Therapy. 
 Overview of FDA’s 
Expedited-Approval 
Designations. 
9- 3/19/20 Spring Break No class  
10- 3/26/20 Regulatory Issues in Gene Therapy  
11- 4/2/20 Regulatory Issues in Cell Therapy  
12- 4/9/20 Regulatory Oversight on Gene and 
Cell Therapy in EU and Japan 
 Regulatory Oversight on 
Gene and Cell Therapy in 
EU. 
 Regulatory Oversight on 
Gene and Cell Therapy in 
Japan. 
13- 4/16/20 Oral Presentations and case 
studies 
Will give details later. 
14- 4/23/20 Oral Presentations and case 
studies 
Will give details later. 
15- 4/30/20 Final Exam Will cover materials from 
week 8- week 12. 
 
